EQRX
NEWS
EQRX was acquired by Revolution Medicines in November 2023.
The life sciences industry might just be filling a bit richer this week as two major venture capital firms announced the closing of new funds.
It was yet another busy week for clinical trial announcements. Take a look.
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
In a late-breaking presentation on Saturday, EQRx and partner CStone Pharmaceuticals will report data from the phase III GEMSTONE-301 study of its anti-PD-L1 antibody sugemalimab.
Moderna will leverage AbCellera’s AI-powered technology to search and analyze natural immune responses in the hopes of identifying antibodies for up to six targets.
Check out where the money went in the life sciences industry this week.
Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.
The deal will give EQRx a pre-transaction enterprise value of $3.65 billion and an immediate $1.8 billion in cash that will be used to advance the development of the company’s pipeline.
The company struck two separate collaborations over the past two days in order to advance the development of new, innovative medications.
JOBS
IN THE PRESS